Clinical Trial Update: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation [Phase 1]

View source ↗

Summary

Phase 1 trial of the SHP2 inhibitor BBP-398 in combination with nivolumab for advanced KRAS-mutant non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BBP-398
• nivolumab (nivolumab)

Snippet

Sponsor: Navire Pharma Inc., a BridgeBio company | Conditions: Non Small Cell Lung Cancer, Solid Tumor | Phase 1 | Status: TERMINATED